|
市場調査レポート
商品コード
1732843
ヒト成長ホルモン市場- 世界の産業規模、シェア、動向、成長機会、予測、製品別、用途別、流通チャネル別、地域別、競合別、2020-2030年Human Growth Hormone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Distribution Channel, By Region and Competition, 2020-2030F |
||||||
カスタマイズ可能
|
|||||||
| ヒト成長ホルモン市場- 世界の産業規模、シェア、動向、成長機会、予測、製品別、用途別、流通チャネル別、地域別、競合別、2020-2030年 |
|
出版日: 2025年05月23日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2~3営業日
|
全表示
- 概要
- 目次
ヒト成長ホルモン(HGH)の世界市場は、2024年に62億1,000万米ドルと評価され、2030年まで13.29%の堅調なCAGRで成長すると予測されています。
医薬品・バイオテクノロジー産業の中で急速に発展しているこの分野は、成長、開発、代謝機能をサポートするために下垂体によって産生される重要なホルモンであるソマトトロピンの使用を中心としています。主な成長促進要因としては、特に小児における成長ホルモン欠乏症(GHD)の有病率の上昇や、加齢に伴うホルモンの減少に対処するための高齢化社会におけるHGH療法への関心の高まりが挙げられます。承認された医療用途に加え、HGHは潜在的なアンチエイジング効果やウェルネス効果についても研究されており、その需要はさらに拡大しています。同市場には、遺伝子組換え型(rhGH)やバイオシミラーを含む幅広い製品があり、注射製剤がセグメントを支配しています。戦略的研究開発イニシアティブ、規制当局の承認、製薬企業間の提携が市場の競合情勢を形成しています。しかし、アクセシビリティの問題や治療費の高さが課題として残っており、また、強化目的の適応外使用に関する倫理的な懸念もあります。
| 市場概要 | |
|---|---|
| 予測期間 | 2026-2030 |
| 市場規模:2024年 | 62億1,000万米ドル |
| 市場規模:2030年 | 131億6,000万米ドル |
| CAGR:2025年~2030年 | 13.29% |
| 急成長セグメント | オンライン薬局 |
| 最大市場 | 北米 |
市場促進要因
成長ホルモン欠乏症(GHD)の有病率の増加
主な市場課題
高コスト
主要市場動向
バイオシミラー
目次
第1章 概要
第2章 調査手法
第3章 エグゼクティブサマリー
第4章 顧客の声
第5章 世界のヒト成長ホルモン市場展望
- 市場規模・予測
- 金額別
- 市場シェア・予測
- 製品別(長時間作用型、その他)
- 用途別(成長ホルモン(GH)欠乏症、ターナー症候群、特発性低身長、プラダー・ウィリー症候群、在胎週数不当過小、その他)
- 流通チャネル別(病院薬局、小売薬局、オンライン薬局、専門薬局)
- 地域別(北米、欧州、アジア太平洋、南米、中東・アフリカ)
- 企業別(2024)
- 製品市場マップ
- 製品別
- 用途別
- 流通チャネル別
- 地域別
第6章 北米のヒト成長ホルモン市場展望
- 市場規模・予測
- 市場シェア・予測
- 北米:国別分析
- 米国
- カナダ
- メキシコ
第7章 欧州のヒト成長ホルモン市場展望
- 市場規模・予測
- 市場シェア・予測
- 欧州:国別分析
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
第8章 アジア太平洋地域のヒト成長ホルモン市場展望
- 市場規模・予測
- 市場シェア・予測
- アジア太平洋地域:国別分析
- 中国
- 日本
- インド
- 韓国
- オーストラリア
第9章 南米のヒト成長ホルモン市場展望
- 市場規模・予測
- 市場シェア・予測
- 南米:国別分析
- ブラジル
- アルゼンチン
- コロンビア
第10章 中東・アフリカのヒト成長ホルモン市場展望
- 市場規模・予測
- 市場シェア・予測
- 中東・アフリカ:国別分析
- アラブ首長国連邦
- サウジアラビア
- 南アフリカ
第11章 市場力学
- 促進要因
- 課題
第12章 市場動向と発展
- 合併と買収
- 製品開発
- 最近の動向
第13章 ポーター分析
第14章 PESTEL分析
第15章 競合情勢
- Novo Nordisk A/S
- Eli Lilly and Company
- Pfizer, Inc.
- Sandoz International GmbH(Novartis AG)
- Genentech, Inc.(Roche)
- Merck KGaA
- Ferring Pharmaceuticals
- Ipsen Pharma
- Teva Pharmaceutical Industries, Ltd.
第16章 戦略的提言
第17章 調査会社について・免責事項
The Global Human Growth Hormone (HGH) Market was valued at USD 6.21 billion in 2024 and is projected to grow at a robust CAGR of 13.29% through 2030. This rapidly evolving sector within the pharmaceutical and biotechnology industry centers on the use of somatotropin-a crucial hormone produced by the pituitary gland-to support growth, development, and metabolic functions. Key growth drivers include the rising prevalence of growth hormone deficiencies (GHD), especially among children, and increased interest in HGH therapy among the aging population to address age-related hormonal decline. In addition to its approved medical applications, HGH is being explored for its potential anti-aging and wellness benefits, further expanding its demand. The market features a wide range of products, including recombinant human growth hormone (rhGH) and biosimilars, with injectable formulations dominating the segment. Strategic R&D initiatives, regulatory approvals, and collaborations among pharmaceutical companies are shaping the market's competitive landscape. However, accessibility issues and high treatment costs remain challenges, alongside ethical concerns about off-label use for enhancement purposes.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 6.21 Billion |
| Market Size 2030 | USD 13.16 Billion |
| CAGR 2025-2030 | 13.29% |
| Fastest Growing Segment | Online Pharmacy |
| Largest Market | North America |
Key Market Drivers
Increasing Prevalence of Growth Hormone Deficiency (GHD)
The growing incidence of Growth Hormone Deficiency (GHD) remains a primary catalyst for the Human Growth Hormone (HGH) market globally. GHD, caused by inadequate hormone secretion from the pituitary gland, significantly affects growth, especially in children, and impacts overall health in adults. Current estimates suggest that GHD occurs in 1 out of every 4,000 to 10,000 live births, with a substantial number of adult-onset cases recorded annually. Greater awareness and improved diagnostic tools have enabled earlier detection and intervention, enhancing patient outcomes. Contributing factors include poor nutrition, increased stress, genetic disorders, and medical conditions involving the hypothalamic-pituitary axis. As access to healthcare broadens, more individuals are seeking evaluation and treatment for growth-related disorders, spurring pharmaceutical companies to develop long-acting therapies and improve patient compliance. This growing patient population continues to drive demand for HGH treatment solutions worldwide.
Key Market Challenges
High Cost
Cost remains a significant barrier in the Global Human Growth Hormone (HGH) Market. The complex production process of recombinant human growth hormone (rhGH), involving high-end biotechnological methods and rigorous quality standards, contributes to elevated prices. The long duration of therapy, often lasting several years, further increases the financial burden on patients and healthcare systems. Limited insurance coverage in certain regions and insufficient public health resources exacerbate access issues. As a result, many patients are unable to afford or maintain treatment, especially in lower-income markets. Addressing affordability through cost-effective production and pricing strategies is essential to broaden access to life-enhancing HGH therapies.
Key Market Trends
Biosimilars
The growing presence of biosimilars is a transformative trend in the Global Human Growth Hormone (HGH) Market. These are biologic products designed to closely resemble original rhGH therapies in terms of safety, efficacy, and quality, but at a more accessible price point. Biosimilars undergo stringent regulatory scrutiny and clinical testing to ensure comparable performance to reference drugs. Their introduction promotes market competition, helping to reduce treatment costs and improve patient access. As biosimilar adoption expands, particularly in cost-sensitive regions, their role in the market is increasing. Nevertheless, regulatory approval processes, interchangeability protocols, and manufacturing consistency remain key considerations. Overall, biosimilars represent a promising path toward greater affordability and availability of HGH treatments.
Key Market Players
- Novo Nordisk A/S
- Eli Lilly and Company
- Pfizer, Inc.
- Sandoz International GmbH (Novartis AG)
- Genentech, Inc. (Roche)
- Merck KGaA
- Ferring Pharmaceuticals
- Ipsen Pharma
- Teva Pharmaceutical Industries, Ltd.
Report Scope:
In this report, the Global Human Growth Hormone (HGH) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Human Growth Hormone (HGH) Market, By Product:
- Long Acting
- Others
Human Growth Hormone (HGH) Market, By Application:
- Growth Hormone (GH) Deficiency
- Turner Syndrome
- Idiopathic Short Stature
- Prader-Willi Syndrome
- Small for Gestational Age
- Other
Human Growth Hormone (HGH) Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Specialty Pharmacy
Human Growth Hormone (HGH) Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Human Growth Hormone (HGH) Market.
Available Customizations:
Global Human Growth Hormone (HGH) Market report with the given Market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional Market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Types
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global Human Growth Hormone Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Product (Long Acting, Others)
- 5.2.2. By Application (Growth Hormone (GH) Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Other)
- 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy)
- 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
- 5.2.5. By Company (2024)
- 5.3. Product Market Map
- 5.3.1. By Product
- 5.3.2. By Application
- 5.3.3. By Distribution Channel
- 5.3.4. By Region
6. North America Human Growth Hormone Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Application
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Human Growth Hormone Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product
- 6.3.1.2.2. By Application
- 6.3.1.2.3. By Distribution Channel
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Canada Human Growth Hormone Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product
- 6.3.2.2.2. By Application
- 6.3.2.2.3. By Distribution Channel
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Mexico Human Growth Hormone Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product
- 6.3.3.2.2. By Application
- 6.3.3.2.3. By Distribution Channel
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Human Growth Hormone Market Outlook
7. Europe Human Growth Hormone Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Application
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Human Growth Hormone Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product
- 7.3.1.2.2. By Application
- 7.3.1.2.3. By Distribution Channel
- 7.3.1.1. Market Size & Forecast
- 7.3.2. France Human Growth Hormone Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product
- 7.3.2.2.2. By Application
- 7.3.2.2.3. By Distribution Channel
- 7.3.2.1. Market Size & Forecast
- 7.3.3. United Kingdom Human Growth Hormone Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product
- 7.3.3.2.2. By Application
- 7.3.3.2.3. By Distribution Channel
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy Human Growth Hormone Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product
- 7.3.4.2.2. By Application
- 7.3.4.2.3. By Distribution Channel
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Human Growth Hormone Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.3. By Product
- 7.3.5.4. By Application
- 7.3.5.5. By Distribution Channel
- 7.3.5.1. Market Size & Forecast
- 7.3.1. Germany Human Growth Hormone Market Outlook
8. Asia-Pacific Human Growth Hormone Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Application
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Human Growth Hormone Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product
- 8.3.1.2.2. By Application
- 8.3.1.2.3. By Distribution Channel
- 8.3.1.1. Market Size & Forecast
- 8.3.2. Japan Human Growth Hormone Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product
- 8.3.2.2.2. By Application
- 8.3.2.2.3. By Distribution Channel
- 8.3.2.1. Market Size & Forecast
- 8.3.3. India Human Growth Hormone Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product
- 8.3.3.2.2. By Application
- 8.3.3.2.3. By Distribution Channel
- 8.3.3.1. Market Size & Forecast
- 8.3.4. South Korea Human Growth Hormone Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product
- 8.3.4.2.2. By Application
- 8.3.4.2.3. By Distribution Channel
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia Human Growth Hormone Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product
- 8.3.5.2.2. By Application
- 8.3.5.2.3. By Distribution Channel
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Human Growth Hormone Market Outlook
9. South America Human Growth Hormone Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Application
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Human Growth Hormone Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Application
- 9.3.1.2.3. By Distribution Channel
- 9.3.1.1. Market Size & Forecast
- 9.3.2. Argentina Human Growth Hormone Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product
- 9.3.2.2.2. By Application
- 9.3.2.2.3. By Distribution Channel
- 9.3.2.1. Market Size & Forecast
- 9.3.3. Colombia Human Growth Hormone Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product
- 9.3.3.2.2. By Application
- 9.3.3.2.3. By Distribution Channel
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Brazil Human Growth Hormone Market Outlook
10. Middle East and Africa Human Growth Hormone Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Application
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. UAE Human Growth Hormone Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product
- 10.3.1.2.2. By Application
- 10.3.1.2.3. By Distribution Channel
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Saudi Arabia Human Growth Hormone Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product
- 10.3.2.2.2. By Application
- 10.3.2.2.3. By Distribution Channel
- 10.3.2.1. Market Size & Forecast
- 10.3.3. South Africa Human Growth Hormone Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product
- 10.3.3.2.2. By Application
- 10.3.3.2.3. By Distribution Channel
- 10.3.3.1. Market Size & Forecast
- 10.3.1. UAE Human Growth Hormone Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition
- 12.2. Product Development
- 12.3. Recent Developments
13. Porter's analysis
14. PESTEL analysis
15. Competitive Landscape
- 15.1. Novo Nordisk A/S
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.2. Eli Lilly and Company
- 15.3. Pfizer, Inc.
- 15.4. Sandoz International GmbH (Novartis AG)
- 15.5. Genentech, Inc. (Roche)
- 15.6. Merck KGaA
- 15.7. Ferring Pharmaceuticals
- 15.8. Ipsen Pharma
- 15.9. Teva Pharmaceutical Industries, Ltd.

